Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) is pleased to announce the appointment of Dr. Nicolas Poirier as new Chief Executive Officer, effective immediately.
NANTES, France (BUSINESS WIRE) Regulatory News:OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) is pleased to announce the appointment of Dr. Nicolas Poirier as new Chief Executive Officer, effective immediately. This appointment follows the decision of the Board of Directors to terminate the.
Corporate Alexis Vandier appointed new Chief Executive Officer to guide the Company through its next phase of growth Strategy focused on leveraging both the Company's clinical portfolio
Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announced today that the leadership team will attend several investor conferences in September and October 2022. Conference
NANTES, France (BUSINESS WIRE) Regulatory News:OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announced today that the leadership team will attend several investor conferences in September and October 2022.Conference details:- H.C. Wainwright 24th Annual Global Investment ConferenceFormat: Fireside cha.